Stockscreener 앱 받기
78.17
0.37%
0.29
시간 외 거래:
78.36
0.19
+0.24%
Illumina Inc 주식(ILMN)의 최신 뉴스
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Illumina, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2024ILMN - ACCESS Newswire
Case study: Professor Sir Shankar Balasubramanian FRS - Royal Society
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc.(ILMN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Illumina, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017ILMN - ACCESS Newswire
Epigenetics Market Is Booming So Rapidly 2025-2032 -Illumina - openPR.com
Illumina (ILMN) and Ovation.io Launch Major Clinical Multiomic D - GuruFocus
Global Molecular Diagnostics Market to Expand at a CAGR of ~9% by 2032 Due to the Rising Demand for Precision Medicine | DelveInsight - GlobeNewswire Inc.
June 13th Options Now Available For Illumina (ILMN) - Nasdaq
Illumina Partners With Ovation.io to Create GLP-1 Dataset for Drug Discovery - marketscreener.com
Illumina (ILMN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Illumina, Ovation.io launching first-of-kind GLP-1 dataset - TipRanks
Illumina and Ovation.io unveil large GLP-1 therapy dataset - Investing.com
Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development - PR Newswire
Even after rising 3.7% this past week, Illumina (NASDAQ:ILMN) shareholders are still down 74% over the past five years - Yahoo Finance
Canaccord Reduces Price Target for Illumina (ILMN) Amid Economic Challenges | ILMN Stock News - GuruFocus
When (ILMN) Moves Investors should Listen - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
Digital Genome Market Set to Witness Significant Growth - openPR.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc. (ILMN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
The path to precision medicine in Indonesia - Illumina
Computational Biology Market New Product Development & Latest - openPR.com
Genetic Testing Market Generated Opportunities, Future Scope - openPR.com
DNA and RNA Sample Preparation Market Projected To Witness - openPR.com
2024 Illumina Epigenetics Research Contest Winner Investigates Blood Transfusion Off-Target Effects - Illumina
Should You Hold Illumina (ILMN)? - MSN
June 6th Options Now Available For Illumina (ILMN) - Nasdaq
It’s all about accessibility: Developing technical training for the MiSeq i100 Series - Illumina
Veraxa makes a SPAC deal; Illumina discloses layoffs - Endpoints News
Resmed Taps Illumina Exec for Chief Investor Relations Officer Role - Medical Product Outsourcing
Microarray Market Projected To Witness Massive Growth, 2025-2032 | Thermo Fisher Scientific Inc.,Illumina Inc. - openPR.com
DNA Microarray Technology Market: Innovations & Opportunities - openPR.com
Cancer Biopsy Market Detailed In New Research Report 2025 | - openPR.com
Genomic Cancer Testing Market Overall Study Report 2025-2032 | - openPR.com
Thomas Kean Jr purchases shares in Illumina and nVent Electric - Investing.com Australia
Resmed Names Salli Schwartz as Chief Investor Relations Officer - The Manila Times
Illumina, Inc. (ILMN): Among Recent Activist Investor Campaigns - Insider Monkey
Controlling Genes Market Detailed in New Research Report By 2032 - openPR.com
Illumina (ILMN) Receives a Buy from Leerink Partners - The Globe and Mail
Illumina, Tempus AI partner to drive genomic testing beyond cancer - MedTech Dive
0.34%
0.46%
자본화:
|
볼륨(24시간):